Ormat CEO Doron Blachar exercises SARs and executes 10b5-1 sale
Rhea-AI Filing Summary
Insider transaction summary: Ormat Technologies CEO Doron Blachar exercised 45,365 Stock Appreciation Rights (SARs) on 09/29/2025 with an exercise price of $63.40 and a market value of $94.71, resulting in issuance of 14,994 shares. Following these transactions and a concurrent open-market sale, the reporting person beneficially owned 35,419 shares. The SARs exercised were part of awards exercisable from 07/01/2022 and expiring 07/01/2026. The sale of 14,994 shares was executed under a 10b5-1 trading plan adopted 06/30/2025 at a weighted-average price of $94.71.
Positive
- Transparent disclosure of SAR exercise, share issuance, and open-market sale with prices and dates provided
- Sale executed under a 10b5-1 plan, indicating pre-established trading instructions to reduce insider timing concerns
- Remaining beneficial ownership disclosed (35,419 shares) after transactions
Negative
- Reduction in executive ownership from 80,784 to 35,419 shares following exercise and sale, which may modestly reduce insider-held stake
- Cash outflow to company equity not detailed — the filing does not state proceeds retained or tax/withholding treatment beyond shares issued and sold
Insights
TL;DR: Routine executive exercise and plan-based sale; standard disclosure for compliance and transparency.
The filing shows the CEO exercised vested SARs and sold a portion of resulting shares under a pre-established 10b5-1 plan. This is a common approach to realize gains while following an approved trading plan to avoid concerns about insider timing. Ownership decreased to 35,419 shares after the transactions, which is disclosed clearly with transaction prices and dates. No indications of atypical insider behavior or undisclosed related-party issues appear in the filing.
TL;DR: Exercise monetized appreciation; limited immediate market impact given modest share count.
The CEO exercised 45,365 SARs with intrinsic value determined by the $94.71 market price versus $63.40 strike, and received 14,994 shares while selling those shares at a weighted-average price of $94.71. The filing quantifies the mechanics of SAR settlement and sale prices range $94.33–$94.89. For investors, this documents executive liquidity but does not by itself alter company fundamentals.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Appreciation Rights (SARs) | 45,365 | $0.00 | -- |
| Exercise | Common Stock | 45,365 | $63.40 | $2.88M |
| Disposition | Common Stock | 30,371 | $94.71 | $2.88M |
| Sale | Common Stock | 14,994 | $94.71 | $1.42M |
Footnotes (1)
- Represents the exercise of Stock Appreciation Rights ("SARs") expiring on July 1, 2026, for which the reporting person exercised all 45,365 shares. This represents the difference between the number of SARs exercised (45,365) and the number of shares issued as a result of the exercise (14,994). The number of shares to be issued under a SAR exercise is determined by multiplying the number of SARs being exercised by the difference between the market value on the date of exercise ($94.71) and the exercise price ($63.40). Represents shares of common stock sold in the open market on September 29, 2025 pursuant to a 10b5-1 Plan adopted by the reporting person on 06/30/2025. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.33 to $94.89, inclusive. The reporting person undertakes to provide to Company, any securityholder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range specified herein.
